Literature DB >> 33974145

Harnessing Metabolomics to Describe the Pathophysiology Underlying Progression in Diabetic Kidney Disease.

Sho Hasegawa1,2, Reiko Inagi3.   

Abstract

PURPOSE OF REVIEW: Diabetic kidney disease (DKD), a leading cause of end-stage kidney disease, is the result of metabolic network alterations in the kidney. Therefore, metabolomics is an effective tool for understanding its pathophysiology, finding key biomarkers, and developing a new treatment strategy. In this review, we summarize the application of metabolomics to DKD research. RECENT
FINDINGS: Alterations in renal energy metabolism including the accumulation of tricarboxylic acid cycle and glucose metabolites are observed in the early stage of DKD, and they finally lead to mitochondrial dysfunction in advanced DKD. Mitochondrial fission-fusion imbalance and dysregulated organelle crosstalk might contribute to this process. Moreover, metabolomics has identified several uremic toxins including phenyl sulfate and tryptophan derivatives as promising biomarkers that mediate DKD progression. Recent advances in metabolomics have clarified the role of dysregulated energy metabolism and uremic toxins in DKD pathophysiology. Integration of multi-omics data will provide additional information for identifying critical drivers of DKD.

Entities:  

Keywords:  Biomarker; Diabetic kidney disease; Metabolomics; Mitochondria; Organelle crosstalk; Uremic toxin

Year:  2021        PMID: 33974145     DOI: 10.1007/s11892-021-01390-8

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  31 in total

Review 1.  Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer.

Authors:  Manjula Darshi; Benjamin Van Espen; Kumar Sharma
Journal:  Am J Nephrol       Date:  2016-07-14       Impact factor: 3.754

2.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

3.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

4.  Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development.

Authors:  Hyun Mi Kang; Seon Ho Ahn; Peter Choi; Yi-An Ko; Seung Hyeok Han; Frank Chinga; Ae Seo Deok Park; Jianling Tao; Kumar Sharma; James Pullman; Erwin P Bottinger; Ira J Goldberg; Katalin Susztak
Journal:  Nat Med       Date:  2014-12-01       Impact factor: 53.440

5.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Authors:  Vlado Perkovic; Meg J Jardine; Bruce Neal; Severine Bompoint; Hiddo J L Heerspink; David M Charytan; Robert Edwards; Rajiv Agarwal; George Bakris; Scott Bull; Christopher P Cannon; George Capuano; Pei-Ling Chu; Dick de Zeeuw; Tom Greene; Adeera Levin; Carol Pollock; David C Wheeler; Yshai Yavin; Hong Zhang; Bernard Zinman; Gary Meininger; Barry M Brenner; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2019-04-14       Impact factor: 91.245

Review 6.  An overview of renal metabolomics.

Authors:  Sahir Kalim; Eugene P Rhee
Journal:  Kidney Int       Date:  2016-09-28       Impact factor: 10.612

7.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245

8.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

9.  Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease.

Authors:  Kumar Sharma; Bethany Karl; Anna V Mathew; Jon A Gangoiti; Christina L Wassel; Rintaro Saito; Minya Pu; Shoba Sharma; Young-Hyun You; Lin Wang; Maggie Diamond-Stanic; Maja T Lindenmeyer; Carol Forsblom; Wei Wu; Joachim H Ix; Trey Ideker; Jeffrey B Kopp; Sanjay K Nigam; Clemens D Cohen; Per-Henrik Groop; Bruce A Barshop; Loki Natarajan; William L Nyhan; Robert K Naviaux
Journal:  J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 10.121

10.  The Nuclear Receptor ESRRA Protects from Kidney Disease by Coupling Metabolism and Differentiation.

Authors:  Poonam Dhillon; Jihwan Park; Carmen Hurtado Del Pozo; Lingzhi Li; Tomohito Doke; Shizheng Huang; Juanjuan Zhao; Hyun Mi Kang; Rojesh Shrestra; Michael S Balzer; Shatakshee Chatterjee; Patricia Prado; Seung Yub Han; Hongbo Liu; Xin Sheng; Pieterjan Dierickx; Kirill Batmanov; Juan P Romero; Felipe Prósper; Mingyao Li; Liming Pei; Junhyong Kim; Nuria Montserrat; Katalin Susztak
Journal:  Cell Metab       Date:  2020-12-09       Impact factor: 31.373

View more
  4 in total

1.  In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease.

Authors:  Bai Linnan; Wang Yanzhe; Zhang Ling; Liu Yuyuan; Chen Sijia; Xie Xinmiao; Li Fengqin; Wang Xiaoxia
Journal:  Front Physiol       Date:  2021-11-30       Impact factor: 4.566

2.  The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease.

Authors:  Qing Zhang; Yanmei Zhang; Lu Zeng; Guowei Chen; Meifang Liu; Hongqin Sheng; Xiaoxuan Hu; Jingxu Su; Duo Zhang; Fuhua Lu; Xusheng Liu; Lei Zhang
Journal:  Front Pharmacol       Date:  2021-11-24       Impact factor: 5.810

3.  NMR-Based Metabolomics to Decipher the Molecular Mechanisms in the Action of Gut-Modulating Foods.

Authors:  Weiwei He; Hanne Christine Bertram
Journal:  Foods       Date:  2022-09-05

Review 4.  Chronic Kidney Disease Cohort Studies: A Guide to Metabolome Analyses.

Authors:  Ulla T Schultheiss; Robin Kosch; Fruzsina Kotsis; Michael Altenbuchinger; Helena U Zacharias
Journal:  Metabolites       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.